Epidermolytic hyperkeratosis explained

Epidermolytic Ichthyosis (EI)
Synonyms:Bullous epidermis ichthyosis

Epidermolytic ichthyosis (EI), is a severe form of dry scaly skin, that initially presents with redness, blisters, erosions, and peeling in a newborn baby.[1] [2] Hyperkeratosis typically develops several months later.[2] Other symptoms include itch, painful fissures, strong body odor, and absence of sweat.[2] Symptoms vary in severity and extent of skin involvement.[1] The two main types are divided into one involving palms and soles and the other without.[2]

EI is caused by a genetic mutation.[2] The condition involves the clumping of keratin filaments.[1] [2]

The condition is rare, affecting around 1 in 200,000 to 300,000 babies.[2]

Signs and symptoms

EI is a severe form of dry scaly skin, that initially presents with redness, blisters, erosions, and peeling in a newborn baby.[1] [3] Hyperkeratosis typically develops several months later.[2] Other symptoms include itch, painful fissures, body odor, and absence of sweat.[2] Symptoms vary in severity and extent of skin involvement.[1] Complications include infection and joint problems.[2] Affected newborns are particularly at risk of dehydration, sepsis, and electrolyte imbalance.[2]

Cause and mechanism

The condition is mostly inherited in an autosomal dominant pattern.[2] To a lesser extent, a recessive form exists.[1] It is caused by genetic mutations in the genes encoding the proteins keratin 1 or keratin 10, resulting in disruption of the structure of the epidermis.[2]

Diagnosis

Diagnosis is by its appearance, skin biopsy, and genetic testing.[2]

The condition can be diagnosed via exam that reveals; generalized redness; thick, generally dark, scales that tend to form parallel rows of spines or ridges, especially near large joints; the skin is fragile and blisters easily following trauma; extent of blistering and amount of scale is variable.

Treatment

Treatment includes applying thick moisturisers.[1] Other therapies include topical and oral retinoids.[1] These include topical N-acetylcysteine, liarozole, and calcipotriol.[2] Bacterial colonisation of skin may be reduced by use of antibacterial soaps, chlorhexidine, and dilute sodium hypochlorite baths.[2]

Research

Gene therapy is being studied for EI.[4]

Epidemiology

The condition is rare, affecting around 1 in 200,000 to 300,000 babies.[2]

History

EI was first classified by its presence or absence in the palms and soles by DiGiovanna and Bale in 1994.[2] [5]

See also

Notes and References

  1. Book: James . William D. . Elston . Dirk . Treat . James R. . Rosenbach . Misha A. . Neuhaus . Isaac . Andrews' Diseases of the Skin: Clinical Dermatology . 2020 . Elsevier . Edinburgh . 978-0-323-54753-6 . 563–565 . 13th . https://books.google.com/books?id=UEaEDwAAQBAJ&pg=PA563 . en . 27. Genodermatoses and congenital anomalies .
  2. Rice . Ashley S. . Crane . Jonathan S. . Epidermolytic Hyperkeratosis . StatPearls . 2023 . 31335043 . StatPearls Publishing.
  3. Rice . Ashley S. . Crane . Jonathan S. . Epidermolytic Hyperkeratosis . StatPearls . 2023 . 31335043 . StatPearls Publishing.
  4. Joosten . M. D. W. . Clabbers . J. M. K. . Jonca . N. . Mazereeuw-Hautier . J. . Gostyński . A. H. . New developments in the molecular treatment of ichthyosis: review of the literature . Orphanet Journal of Rare Diseases . 15 July 2022 . 17 . 1 . 269 . 10.1186/s13023-022-02430-6 . free . 35840979 . 9287901 . 1750-1172.
  5. DiGiovanna JJ, Bale SJ . Clinical heterogeneity in epidermolytic hyperkeratosis . Arch Dermatol . 130 . 8 . 1026–35 . August 1994 . 8053700 . 10.1001/archderm.130.8.1026.